Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA matching of donors and recipients. This has its origin in the variation between the exomes of the two, which provides the basis for minor histocompatibility antigens (mHA). The mHA presented on the HLA class I and II molecules and the ensuing T cell response to these antigens results in graft vs. host disease. In this paper, results of a whole exome sequencing study are presented, with resulting alloreactive polymorphic peptides and their HLA class I and HLA class II (DRB1) binding affinity quantified. Large libraries of potentially alloreactive recipient peptides binding both sets of molecules were identified, with HLA-DRB1 generally presenti...
Minor histocompatibility antigens (mHAs), recipient-derived peptide epitopes presented on the cell s...
Copyright © 2014 Heike Kunze-Schumacher et al. This is an open access article distributed under the ...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is routinely used to treat hematopoie...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Donor T-cell mediated graft versus host (GVH) effects may result from the aggregate alloreactivity t...
Quantitative relationship between the magnitude of variation in minor histocompatibility antigens (m...
Immune reconstitution kinetics and subsequent clinical outcomes in HLA-matched recipients of allogen...
Quantitative relationship between the magnitude of variation in minor histocompatibility antigens (m...
<div><p>Allogeneic stem cell transplantation can be a curative treatment for hematological malignanc...
In hematopoietic stem cell transplantation (HSCT), the outcome is predicted using HLA-matching proce...
Minor histocompatibility antigens (mHAs), recipient-derived peptide epitopes presented on the cell s...
Copyright © 2014 Heike Kunze-Schumacher et al. This is an open access article distributed under the ...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is routinely used to treat hematopoie...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA m...
Donor T-cell mediated graft versus host (GVH) effects may result from the aggregate alloreactivity t...
Quantitative relationship between the magnitude of variation in minor histocompatibility antigens (m...
Immune reconstitution kinetics and subsequent clinical outcomes in HLA-matched recipients of allogen...
Quantitative relationship between the magnitude of variation in minor histocompatibility antigens (m...
<div><p>Allogeneic stem cell transplantation can be a curative treatment for hematological malignanc...
In hematopoietic stem cell transplantation (HSCT), the outcome is predicted using HLA-matching proce...
Minor histocompatibility antigens (mHAs), recipient-derived peptide epitopes presented on the cell s...
Copyright © 2014 Heike Kunze-Schumacher et al. This is an open access article distributed under the ...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is routinely used to treat hematopoie...